Labiana Posted Revenues of Over €66 Million in 2024, Up 13%
- Both the animal and human health divisions grew by double digits last year, with revenue increases of 10.6% and 16%, respectively
- The company tripled its EBITDA to €9.43 million and reported an EBIT of €4.96 million
Madrid, April 23, 2025 – Labiana, the pharmaceutical company specializing in animal and human health and listed on BME Growth, closed the 2024 fiscal year with revenues of €66.26 million, representing a 13.3% increase compared to the previous year. The growth rises to 18.4% when excluding the contribution from the Serbian subsidiary, which the company divested in the first half of 2024.
By business segment, both the animal and human health divisions achieved double-digit growth last year. The human health segment increased its revenues by 16% compared to 2023, driven mainly by the expansion of the CDMO (Contract Development and Manufacturing Organization) area during this period. Meanwhile, the animal health segment saw a 10.6% increase in sales, fueled by growth in both the CDMO area and proprietary products in Spain and Europe, as well as an 8.9% rise in sales in the companion animals division.
The increase in revenues was also reflected in the company’s profitability, as its EBITDA nearly tripled to €9.43 million, compared to €3.29 million the previous year. Operating profit (EBIT) also improved significantly, reaching a positive result of €4.96 million in 2024.
The company’s net financial debt to adjusted EBITDA ratio was also reduced to 2.96x, strengthening Labiana’s capital structure without compromising its capacity for the development and manufacturing of biological products or its commercial ties with Eastern Europe.
Labiana attributes these results to the implementation of various recent management and operational measures, including the appointment of Sandra Villagrasa as Group General Manager, the financing agreement signed with Miralta Finance Bank and Blantyre Capital to support the business plan and enhance the capital structure, and the divestment of the Serbian subsidiary, which enabled deleveraging and its removal from the Group’s consolidation perimeter.
According to Manuel Ramos, CEO of Labiana, “This progress is the result of key strategic decisions. While we continue working on our efficiency and operational improvement plans, our goal remains to consolidate and expand our presence in the animal and human health markets by investing in innovation and strengthening our relationships with clients and strategic partners.”
Earnings Results Presentation Webinar
Today, Wednesday, April 23, at 10:00 AM, a results presentation webinar will be held via teleconference to explain the most relevant aspects of the business segments’ performance and financial results. The presentation is open to attendees upon prior registration through the following link.
About Labiana
Labiana Health is an independent, integrated international leader in animal and human health, with a diversified portfolio of products and businesses and a broad client base of top-tier companies with long-lasting relationships built on trust. It has subsidiaries in Spain, Serbia, Turkey, and Mexico, with production centers distributed between Spain and Serbia. Labiana’s products are present in over 150 markets, with product registrations in more than 90 countries. The group has two differentiated and complementary business lines: contract manufacturing in both veterinary and human health, which provides stability and income visibility, and the development, manufacturing, and commercialization of its own products in both animal and human health, driving growth. The company debuted on BME Growth in June 2022, becoming the first veterinary company to list on Spain’s BME Growth Market.
FORWARD-LOOKING STATEMENTS
This communication may contain information and forward-looking statements or declarations regarding LABIANA. It may also include financial projections and/or estimates with their underlying assumptions, statements concerning plans, objectives, and expectations regarding future operations, investments, synergies, products, and services, as well as statements about future results. Forward-looking statements are not historical facts and are generally identified by the use of terms such as “expects,” “anticipates,” “believes,” “intends,” “estimates,” and similar expressions.
While LABIANA believes that the expectations reflected in such statements are reasonable, investors and shareholders of LABIANA are cautioned that forward-looking information and statements are subject to risks and uncertainties, many of which are difficult to predict and are generally beyond the control of LABIANA. These factors could cause actual results and developments to differ significantly from those expressed, implied, or projected in the forward-looking information and statements.
Such risks and uncertainties include those identified in documents submitted by LABIANA to BME Growth, which are publicly accessible. It is recommended not to make decisions based on forward-looking statements, as they refer solely to the date on which they were made, do not constitute a guarantee of future results, and have not been audited by LABIANA’s auditors.
All forward-looking statements or declarations, whether oral or written, made by LABIANA or any of its board members, executives, employees, or representatives are expressly subject to these warnings. The forward-looking statements or declarations included in this document are based on the information available to LABIANA as of the date of this communication.
Leave a Comment